185 related articles for article (PubMed ID: 2257218)
1. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF
Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
6. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
[TBL] [Abstract][Full Text] [Related]
7. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
8. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
9. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
[TBL] [Abstract][Full Text] [Related]
10. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
[TBL] [Abstract][Full Text] [Related]
12. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
[TBL] [Abstract][Full Text] [Related]
14. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
Marais R; Spooner RA; Light Y; Martin J; Springer CJ
Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
[TBL] [Abstract][Full Text] [Related]
15. A cytotoxic agent can be generated selectively at cancer sites.
Bagshawe KD; Springer CJ; Searle F; Antoniw P; Sharma SK; Melton RG; Sherwood RF
Br J Cancer; 1988 Dec; 58(6):700-3. PubMed ID: 3265633
[TBL] [Abstract][Full Text] [Related]
16. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
17. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
18. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG
Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849
[TBL] [Abstract][Full Text] [Related]
19. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
20. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
